Rynek i konsumenci · 01/11/2002
FDA to Exempt Hormone Replacement Therapy Products from Child-Resistant Packaging Requirements
The US FDA is amending its child-resistant packaging rules to exempt hormone replacement therapy (HRT) products that rely solely on progestogen or estrogen substances, expanding current exemptions for some HRT products
Source: Federal Register — Consumer Product Safety CommissionOpen original release →